Xhale, Inc. announced today that it has submitted to the Food and
Drug Administration (FDA) the first Biomarker Qualification package for a Drug Development Tool for medication adherence monitoring.
Assurance® Alar One-Sense™ Pulse Oximetry Sensor to be
Presented in Two Clinical Abstracts and an Educational Session at Society for Technology in Anesthesiology Meeting. Research shows faster response time and the ability to identify abnormal breathing patterns.
Assurance Alar One-Sense Pulse Oximetry Sensor highlighted in three clinical presentations at American Society of Anesthesiologists annual Meeting in October.
Assurance Biosense, Inc., a subsidiary of Xhale, Inc., today announced receipt from the U.S. Food and Drug Administration (FDA) of 510(k) clearance to market its Assurance® Alar Sensor for monitoring of oxygen saturation of arterial hemoglobin (SpO2) and pulse rate from the nasal ala of adult and pediatric patients.
Satisfied Users & 
Approved Press Releases
